REDMILE GROUP
REDMILE GROUP is a Seed, Series A, Series B and Series C+ fund in the US and Europe writing $5M–$50M checks into Healthcare, life-sciences, biotechnology, pharmaceuticals, medical-devices and healthcare-services.
- Stages
- Seed, Series A, Series B, Series C+
- Sectors
- Healthcare, life-sciences, biotechnology, pharmaceuticals, medical-devices, healthcare-services
- Check size
- $5M–$50M
- Invests in
- US-wide, Europe
- Actively investing
- Yes
- Founded
- 2007
- Assets under management
- $6.5B
- Website
- redmilegroup.com
Thesis
Redmile Group, founded in 2007, is a specialized investment firm with a deep sector focus on healthcare and life sciences, including biotechnology, pharmaceuticals, medical devices, and healthcare services. They operate across venture capital, private equity, and hedge fund strategies, employing a multi-stage investment approach that includes venture, growth, and crossover rounds, as well as post-IPO equity investments. Their geographic focus is primarily North America and Europe, with a strong emphasis on the United States. Redmile Group takes significant, concentrated positions in companies they believe will deliver outsized returns, indicating a conviction-driven approach. As of December 31, 2025, their AUM was approximately $4.7 billion, with other estimates placing it around $6.5 billion. They typically invest between $5 million and $50 million per deal.
Common questions
Does REDMILE GROUP invest at the Seed stage?
Yes. REDMILE GROUP lists Seed, Series A, Series B and Series C+ among the stages it invests in.
What check size does REDMILE GROUP write?
REDMILE GROUP writes $5M–$50M checks.
Where does REDMILE GROUP invest?
REDMILE GROUP invests in the US and Europe.